This page was automatically translated and accurateness of translation is not guaranteed. Please refer to the English version for a source text.

Measuring Atomoxetine and Aroxybutynin In Patients With OSA

Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of Atomoxetine/Aroxybutynin (AD109) to Atomoxetine Alone or Placebo in Obstructive Sleep Apnea

Спонсоры

Ведущий спонсор: Apnimed

Источник Apnimed
Краткое содержание

MARIPOSA is a randomized, double blind, placebo-controlled, parallel-arm 1-month study of AD109 in participants with OSA. Enrolled participants will be randomized to one of 5 parallel treatment arms.

Подробное описание

MARIPOSA is a randomized, double blind, placebo-controlled, parallel-arm 1-month study in participants with OSA. A screening visit and polysomnograms (PSGs) will be conducted to establish that each participant meets study enrollment criteria. The screening PSGs will serve as the baseline for the PSGs conducted during the 3rd and 4th weeks of drug treatment. Enrolled participants will be randomized to one of 5 parallel treatment arms. The first week of dosing will be with a lower dose run-in of AD109 (or corresponding single-drug component or placebo), followed by the full dose taken in weeks 2-4. One combination tablet is taken each night immediately before lights out. A total of approximately 260 participants will be enrolled.

Общий статус Not yet recruiting
Дата начала 2021-09-30
Дата завершения 2022-04-01
Дата первичного завершения 2022-04-01
Фаза Phase 2
Тип исследования Interventional
Первичный результат
Мера Временное ограничение
Change in AHI (4% definition) 1 month
Вторичный результат
Мера Временное ограничение
Change in AHI (4% definition) 1 month
Change in AHI (4% definition) 1 month
Change in HB 1 month
Регистрация 260
Состояние
Вмешательство

Тип вмешательства: Drug

Название вмешательства: AD109 (atomoxetine/aroxybutynin)

Описание: Matching (blinded) formulated AD109 oral tablet administered before sleep

Тип вмешательства: Drug

Название вмешательства: Atomoxetine Hydrochloride

Описание: Matching (blinded) formulated atomoxetine oral tablet administered before sleep

Этикетка Arm Group: Atomoxetine

Тип вмешательства: Drug

Название вмешательства: Placebo

Описание: Matching (blinded) formulated placebo oral tablet administered before sleep

Этикетка Arm Group: Placebo

Приемлемость

Критерии:

Inclusion Criteria: - Between 18 to 65 years of age for men and 75 for women, inclusive - AHI between 10 to 45 with <25% events central or mixed apneas - BMI between 18.5 and 38 kg/m2 Exclusion Criteria: - Current clinically significant sleep disorder other than OSA - Clinically significant craniofacial malformation or grade ≥3 tonsillar hypertrophy. - Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 drugs for control (combination drugs count as 1 drug). - Clinically significant neurological disorder, including epilepsy/convulsions. - History of clinically significant urinary retention, gastric retention or other severe decreased gastrointestinal motility condition - Severe or frequent gastroesophageal reflux or constipation - Participants with a history of using devices for OSA treatment, including CPAP, oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 2 weeks prior to first PSG and are not used during participation in the study

Пол:

All

Минимальный возраст:

18 Years

Максимальный возраст:

75 Years

Здоровые волонтеры:

No

Общий контакт Контактная информация отображается только при наборе участников исследования.
Дата проверки

2021-06-01

Ответственная сторона

Тип: Sponsor

Имеет расширенный доступ No
Состояние Просмотр
Количество рук 5
Группа вооружений

Метка: AD109 Dose 1

Тип: Experimental

Описание: AD109 Dose 1

Метка: AD109 Dose 2

Тип: Experimental

Описание: AD109 Dose 2

Метка: AD109 Dose 3

Тип: Experimental

Описание: AD109 Dose 3

Метка: Atomoxetine

Тип: Active Comparator

Описание: Atomoxetine

Метка: Placebo

Тип: Placebo Comparator

Описание: Placebo

Акроним MARIPOSA
Данные пациента No
Информация о дизайне исследования

Распределение: Randomized

Модель вмешательства: Parallel Assignment

Первичное назначение: Treatment

Маскировка: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

analytics
Подписаться